News about "Eli Lilly"

Innovent and Lilly Partner to Commercialise Verzenios in China

Innovent Biologics and Eli Lilly have signed a commercialisation agreement for Verzenios (abemaciclib) in mainland China, expanding access to the CDK4/6 inhibitor for cancer patients.

Eli Lilly | 01/07/2026 | By News Bureau

CHMP Recommends Lilly's Jaypirca for CLL Treatment in EU

CHMP has recommended Lilly’s Jaypirca (pirtobrutinib) for EU approval in adults with chronic lymphocytic leukemia (CLL), potentially expanding its use across all lines of therapy.

Eli Lilly | 29/06/2026 | By News Bureau

Lilly Completes Acquisition of Centessa to Advance Sleep Disorder Therapies

Lilly expands its neuroscience portfolio with the acquisition of Centessa Pharmaceuticals to accelerate treatments for narcolepsy and related sleep disorders.

Eli Lilly | 26/06/2026 | By News Bureau

Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL

Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.

Eli Lilly | 15/06/2026 | By News Bureau

Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes

Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.

Eli Lilly | 10/06/2026 | By News Bureau |  101

Hanmi Signs Licensing Agreement with Lilly for Sonefpeglutide

Hanmi has signed a licensing agreement with Lilly for sonefpeglutide (LAPSGLP-2 analog), granting rights to develop and commercialize the investigational therapy across multiple indications.

Eli Lilly | 03/06/2026 | By News Bureau

Eli Lilly and Company's Ebglyss Shows Four-Year Durable Relief in Atopic Dermatitis Study

Long-term phase III data reveal sustained skin clearance and itch reduction with once-monthly dosing in eczema patients.

Eli Lilly | 30/03/2026 | By News Bureau |  136

Eli Lilly Eyes USD 2 Billion AI Drug Discovery Deal with Insilico Medicine

Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.

Eli Lilly | 30/03/2026 | By Darshana |  187

Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial

Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.

Eli Lilly | 20/03/2026 | By News Bureau |  168

EBGLYSS Achieves Phase-III Success in Children with Moderate-to-Severe Atopic Dermatitis

In phase-III ADorable-1 study, EBGLYSS demonstrated strong efficacy in paediatric atopic dermatitis. The treatment also showed meaningful gains in higher efficacy endpoints and itch relief, alongside a safety profile consistent with previous studies and no reported injection site pain.

Eli Lilly | 17/03/2026 | By Akanki |  106